IP Library › Granted Patent US 7,504,387
Granted Patent B2
US 7,504,387 · App. 11/105,163 · Granted Mar 17, 2009

Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,504,387
App. No.
11/105,163
Granted
Mar 17, 2009
Kind
B2
Abstract

The invention provides compositions and methods useful for the treatment and/or prevention of interstitial cystitis and/or a related urinary tract condition in man or in animals. Specifically, provided are compositions specially formulated for direct instillation into the bladder and/or parenteral use in the treatment and/or prevention of interstitial cystitis. Compositions adapted for direct instillation into the bladder and/or for systemic administration are provided comprised of therapeutic amounts of: chondroitin sulfate in combination with hyaluronan (hyaluronic acid) are provided. Compositions adapted for direct instillation into the bladder and/or for systemic administration are also provided comprised of therapeutic amounts of: chondroitin sulfate, hyaluronan (hyaluronic acid) and N-acetyl D-glucosamine.

Claims (8)

1. A method for treatment of interstitial cystitis or a related urinary tract condition in man or in animals, comprising direct instillation into the bladder of said man or animals a therapeutic amount of a composition consisting essentially of chondroitin sulfate, hyaluronan, and N-acetyl D-glucosamine.

2. The method of claim 1 , wherein said therapeutic amount of chondroitin sulfate comprises from between about 0.5 grams to about 1.5 grams of a suitable chondroitin sulfate per unit dose of the composition.

3. The method of claim 2 , wherein said suitable chondroitin sulfate is CS4 chondroitin sulfate.

4. The method of claim 2 , wherein said suitable chondroitin sulfate is CS6 chondroitin sulfate.

5. The method of claim 2 , wherein said suitable chondroitin sulfate is a mixture of CS4 chondroitin sulfate and CS6 chondroitin sulfate.

6. The method of claim 1 , wherein said therapeutic amount of hyaluronan is from about 10 mg to about 50 mg of hyaluronan per unit dose of the composition.

7. The method of claim 1 , where said therapeutic amount of N-acetyl D-glucosamine is from about 0.5 grams to about 1.5 grams of N-acetyl D-glucosamine per unit dose of the composition.

8. The method of claim 1 , wherein said composition is a sterile solution.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
To: ARTHRODYNAMIC HOLDINGS, LLC
Reel/Frame 040854/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2008
From: MARCUM, FRANK D.
To: ARTHRODYNAMIC TECHNOLOGIES, ANIMAL HEALTH DIVISION, INC.
Reel/Frame 020610/0637 →